Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Steve Nicholls Articles

Targeting PCSK9 inhibitors to the right patient

Targeting PCSK9 inhibitors to the right patient

Professor Stephen J Nicholls MBBS PhD, Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia  The clinical development of pharmacological inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) has received considerable attention by virtue of the expectation that these treatments would have the potential to…

read more »
‘Game changing’ management of LDL-C

‘Game changing’ management of LDL-C

Professor Steven Nicholls, Professor of Cardiology at the University of Adelaide, Australia, explores the future management of patients with elevated low density lipoprotein cholesterol (LDL-C) and the new treatment options which will be available to clinicians.

read more »
Current status of IVUS studies of plaque burden: what next with GLAGOV?

Current status of IVUS studies of plaque burden: what next with GLAGOV?

Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…

read more »
PlayESC Congress 2015 buzz: Novel LDL lowering treatments

ESC Congress 2015 buzz: Novel LDL lowering treatments

Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the PCSK9 inhibitors versus CETP inhibitors

read more »
PlayPCSK9 therapeutics – the next story?

PCSK9 therapeutics – the next story?

Results from a Phase I trial of a new approach to PCSK9 therapeutics, small interfering RNA (siRNA) were presented at ESC Congress 2015. Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the findings and potential clinical implications of this strategy: what would be the…

read more »
PlayHow will PCSK9 inhibitors be used in practice?

How will PCSK9 inhibitors be used in practice?

Professor Steven Nicholls, Professor of Cardiology at the University of Adelaide and the inaugural SAHMRI Heart Foundation Heart Health Theme Leader at the South Australian Health and Medical Research Institute, Australia, discusses the patients in whom these new treatments will be used initially and speculates…

read more »
PlayDoes PCSK9 inhibition impact atherosclerosis?

Does PCSK9 inhibition impact atherosclerosis?

Research shows that progression of atherosclerosis – narrowing of the coronaries due to high density lipoprotein cholesterol (HDL-C) – may be reduced if statins are combined with new PCSK9 inhibitors. This could prevent heart attacks according to one of the trialists, Professor Steve Nicholls from…

read more »
Does PCSK9 inhibition on top of statin therapy offer the possibility of further reducing plaque burden?

Does PCSK9 inhibition on top of statin therapy offer the possibility of further reducing plaque burden?

Stephen J Nicholls MBBS PhD South Australian Health and Medical Research Institute, University of Adelaide, Australia Technical advances in arterial wall imaging have enabled the visualization of the full burden of atherosclerotic plaque. When applied in serial imaging studies of anatomically matched arterial segments, it…

read more »